Compare UVE & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | MLTX |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.9M | 972.7M |
| IPO Year | 1992 | N/A |
| Metric | UVE | MLTX |
|---|---|---|
| Price | $34.53 | $13.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $40.00 | $36.33 |
| AVG Volume (30 Days) | 163.7K | ★ 1.8M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 70.32 | N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $1,580,798,000.00 | N/A |
| Revenue This Year | $1.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | ★ 4.61 | N/A |
| 52 Week Low | $18.72 | $5.95 |
| 52 Week High | $35.84 | $62.75 |
| Indicator | UVE | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 49.48 |
| Support Level | $32.50 | $13.32 |
| Resistance Level | $35.40 | $15.40 |
| Average True Range (ATR) | 0.95 | 0.77 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 80.71 | 31.64 |
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.